LOS ANGELES (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.
from Reuters: Health News https://ift.tt/2HnReKK
via IFTTT
from Reuters: Health News https://ift.tt/2HnReKK
via IFTTT
Post a Comment